Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CETP | P11597 | 3/20 | 0.39 |
| ▸ | LAP3 | P28838 | 5/20 | 0.39 |
| ▸ | ANPEP | P15144 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4641415 | 0.80 | ACP3 (0.51) | ACP3TSHRLAP3ANPEPCYP2D6 | |
| SCHEMBL5032697 | 0.79 | ACP3 (0.50) | ACP3TSHRLAP3ANPEPCYP2D6 | |
| SCHEMBL4145464 | 0.78 | ACP3 (0.44) | ACP3LAP3ANPEPCYP2D6 | |
| SCHEMBL28746406 | 0.78 | ACP3 (0.56) | ACP3TSHRLAP3ANPEPCYP2D6 | |
| SCHEMBL445039 | 0.78 | ACP3 (0.56) | ACP3TSHRLAP3ANPEPCYP2D6 | |
| SCHEMBL11541664 | 0.77 | ACP3 (0.49) | ACP3LAP3ANPEPCYP2D6 | |
| SCHEMBL4167079 | 0.76 | CETP (0.62) | HTTSMN1; SMN2TSHRCETPPTPN2 | |
| SCHEMBL28547996 | 0.76 | ACP3 (0.54) | ACP3TSHRLAP3ANPEPCYP2D6 | |
| SCHEMBL14440192 | 0.75 | TSHR (0.49) | HTTSMN1; SMN2TSHRCETPPTPN2 | |
| SCHEMBL11316147 | 0.75 | ACP3 (0.46) | ACP3TSHRLAP3ANPEPCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029939-A1 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2009-01-29 | — | — | US | disclosed |
| EP-1742642-B1 | PHOSPHONATE ANALOGS OF HIV INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2008-10-15 | — | — | EP | disclosed |
| US-20080076738-A1 | Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds | GILEAD SCIENCES, INC. | 2008-03-27 | — | — | US | disclosed |
| US-7253180-B2 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1742642-A2 | PHOSPHONATE ANALOGS OF HIV INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2007-01-17 | — | — | EP | disclosed |
| US-20060217410-A1 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2006-09-28 | — | — | US | disclosed |
| US-20060116356-A1 | Phosphonate analogs of HIV integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2006-06-01 | — | — | US | disclosed |
| WO-2005117904-A2 | PHOSPHONATE ANALOGS OF HIV INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| EP-1558613-A2 | PRE-ORGANIZED TRICYCLIC INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-08-03 | — | — | EP | disclosed |
| US-20040167124-A1 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040157804-A1 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2004-08-12 | — | — | US | disclosed |
| WO-2004035576-A2 | PRE-ORGANIZED TRICYCLIC INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2004035577-A2 | PRE-ORGANIZED TRICYCLIC INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217410-A1 | Pre-organized tricyclic integrase inhibitor compounds | CCNI, INTS6, CCNE1 | ACP3 3659/4885HTT 4510/4885SMN1; SMN2 3377/4885 |
| US-20040167124-A1 | Pre-organized tricyclic integrase inhibitor compounds | INTS6, INTS9, MUS81 | ACP3 3654/4885HTT 3966/4885SMN1; SMN2 3976/4885 |
| US-20040157804-A1 | Pre-organized tricyclic integrase inhibitor compounds | INTS6, INTS9, MUS81 | ACP3 3654/4885HTT 3966/4885SMN1; SMN2 3976/4885 |
| US-20090029939-A1 | Pre-organized tricyclic integrase inhibitor compounds | MUS81, CDKL4, INTS6 | ACP3 3259/4885HTT 4163/4885SMN1; SMN2 3403/4885 |
| US-20060116356-A1 | Phosphonate analogs of HIV integrase inhibitor compounds | TYMP, PNP, PIKFYVE | ACP3 554/4885HTT 4059/4885SMN1; SMN2 4116/4885 |
| US-20080076738-A1 | Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds | TYMP, PNP, PIKFYVE | ACP3 554/4885HTT 4059/4885SMN1; SMN2 4116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.